

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
8 May 2003 (08.05.2003)

PCT

(10) International Publication Number  
**WO 03/037361 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 38/00**

(21) International Application Number: PCT/DK02/00727

(22) International Filing Date:  
1 November 2002 (01.11.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
PA 2001 01628 2 November 2001 (02.11.2001) DK

(71) Applicant: NOVO NORDISK A/S [DK/DK]; Novo Allé,  
DK-2880 Bagsvaerd (DK).

(72) Inventors: SØRENSEN, Brit, Binow; 1 Mari-  
anelundsvej, DK-3460 Birkerød (DK). PETERSEN,  
Lars, Christian; 4 Havevej, DK-2970 Hørsholm (DK).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC,  
VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: USE OF TISSUE FACTOR AGONIST OR TISSUE FACTOR ANTAGONIST FOR TREATMENT OF CONDITIONS  
RELATED TO APOPTOSIS

(57) Abstract: The present invention relates to use of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF  
antagonist in therapeutic treatment of pathological conditions increased or decreased cell apoptosis is required.



**WO 03/037361 A2**

## USE OF TISSUE FACTOR AGONIST OR TISSUE FACTOR ANTAGONIST FOR TREATMENT OF CONDITIONS RELATED TO APOPTOSIS

### FIELD OF THE INVENTION

5 A novel cell regulating activity of a tissue factor (TF) agonist such as, for example, coagulation factor VII (FVII) or a tissue factor antagonist such as, for example, inactivated coagulation factor VIIa (FVIIai) on cells expressing tissue factor (TF) has been described. The present invention relates to a method for regulating cell apoptosis by contacting the cell with a TF agonist, e.g. FVIIa, or a TF antagonist, e.g. FVIIai. The invention also relates to the  
10 use of FVIIa or another TF agonist, or FVIIai or another TF antagonist for the preparation of a medicament for regulation of conditions related to apoptosis in a patient. Moreover the present invention relates to a method of treating conditions in a patient, where a decrease or an increase of apoptosis is required.

### BACKGROUND OF THE INVENTION

15 The extrinsic pathway of blood coagulation is initiated when FVIIa circulating in plasma binds to the integral-membrane protein, tissue factor (TF). The involvement of FVIIa as a proteolytic enzyme in the blood coagulation cascade is believed to be confined to the extracellular leaflet of TF expressing cells. Studies of a putative intracellular signalling capacity of FVIIa have shown that it induce mobilisation of intracellular free calcium ( $\text{Ca}^{2+}$ ) in a human bladder carcinoma cell line, which constitutively express TF and in umbelical vein endothelial cells which were pre-treated with interleukin-1 to express TF, but have failed to show  
20 any cytokine-like activation of intracellular tyrosine kinases. Recent reports indicate that TF may influence important biological functions other than coagulation, such as angiogenesis, embryo vascularization and tumor metastasis. At present, however, it is unclear how TF contributes to these biological processes.  
25

A potential role for the TF cytoplasmic domain in signal transduction is indicated in studies that showed prometastatic function of TF is critically dependent on the TF cytoplasmic domain. Further, TF cytoplasmic domain is shown to interact with actin-binding protein 280 (ABP-280) and supports cell adhesion and migration through recruitment of ABP-280 to  
30 TF-mediated adhesion contacts.

However, TF has also been shown to participate certain types of cell signaling by serving as a cofactor for its physiological ligand FVIIa in an extracellular signaling by a putative proteolytic mechanism. For example, binding of FVIIa to cell surface TF is shown to induce

intracellular  $\text{Ca}^{2+}$  oscillations in a number of TF expressing cells, transient phosphorylation of tyrosine in monocytes, activation of MAP kinase, alteration in gene expression in fibroblasts and enhanced expression of urokinase receptor in tumor cells. Catalytically inactive FVIIa (FVIIai) fails to induce many of the above signaling responses, from  $\text{Ca}^{2+}$  oscillations to MAP kinase activation and gene reduction, and it appears that the catalytic activity of FVIIa may be required for at least some TF-FVIIa-mediated signal transduction. At present, not much is known about signaling pathway(s) that are induced by proteolytically active FVIIa.

Normal tissues in the body are formed either by cells that have reached a terminally differentiated state and no longer divide or by cells that die after a period of time and are replaced from a pool of dividing cells. For example, nervous tissue is formed early in development and the cells of the nervous system reach a terminally differentiated state soon after birth. In general, when nervous tissue is damaged, the nerve cells are incapable of dividing and, therefore, the loss of function due to the damaged nerve cells is not repaired.

In comparison to the nervous system, the skin is composed of stratified layers of epithelial cells, in which the upper (outer) layer of cells constantly is sloughed off and the lower layer of cells divides so as to replace the lost cells. Thus, the skin is an example of a tissue that is maintained in a steady-state, where the number of cells that are lost is equivalent to the number of new cells produced.

In some tissues such as skin, the steady-state is maintained, in part, due to a process of programmed cell death, in which the cells are genetically "programmed" to die after a certain period of time. A cell experiencing programmed cell death undergoes morphologic changes characteristic of apoptosis, including, for example, fragmentation of its DNA and collapse of its nucleus.

Apoptosis is particularly prominent during the development of an organism, where cells that perform transitory functions are programmed to die after their function no longer is required. In addition, apoptosis can occur in cells that have undergone major genetic alterations, thus providing the organism with a means to rid itself of defective and potentially cancer forming cells. Apoptosis also can be induced due to exposure of an organism to various external stimuli, including, for example, bacterial toxins, ethanol and ultraviolet radiation. Chemotherapeutic agents for treating cancer also are potent inducers of apoptosis.

## DESCRIPTION OF THE INVENTION

The present invention relates to usage of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions that can be related to apoptosis.

Generally, the blood components, which participate in what has been referred to as the coagulation "cascade" are proenzymes or zymogens, enzymatically inactive proteins, which are converted to proteolytic enzymes by the action of an activator, itself an activated clotting factor. Coagulation factors that have undergone such a conversion and generally referred to as "active factors", and are designated by the addition of the letter "a" to the name of the coagulation factor (e.g. factor VIIa).

The term "FVII" or "factor VII" means "single chain" (zymogenic) coagulation factor VII. The term "Factor VIIa", or "FVIIa" means "two chain" activated coagulation factor VII cleaved by specific cleavage at the Arg152-Ile153 peptide bond. FVII and FVIIa may be purified from blood or produced by recombinant means. It is evident that the practice of the methods described herein is independent of how the purified factor VIIa is derived and, therefore, the present invention is contemplated to cover use of any factor FVII or FVIIa preparations suitable for use herein. Preferred are human FVIIa.

The term "modified factor VII", "inactivated FVII", or "FVIIai" is intended to mean FVIIa having at least one modification, which modification substantially inhibits the ability of modified FVIIa to activate FX and/or FIX. This modification may be in the catalytic centre of FVIIa. The terms may be used interchangeably. Such modification includes amino acid substitution (or replacement) of one or more of the catalytic triad residues Ser344, Asp142 and His193, and also includes modification of catalytic triad residues with serine protease inhibitors such as organo-phosphor compounds, sulfanylfuoride, peptide halomethyl ketone or azapeptide. Modifications also includes amino acid deletions and insertions. FFR-FVIIa is one example of a FVIIai derivative obtained by blocking of the active centre of FVIIa with the irreversible inhibitor, D-phenylalanine-L-phenylalanine-L-argininine chloromethyl ketone (FFR cmk). Other suitable FVIIai derivatives are inactivated FVIIa obtained or obtainable by blocking the active centre with L-phenylalanine-L-phenylalanine-L-argininine chloromethyl ketone, dansyl-L-phenylalanine-L-phenylalanine-L-argininine chloromethyl ketone, or dansyl-D-phenylalanine-L-phenylalanine-L-argininine chloromethyl ketone, Preferred is FFR-FVIIa (FVIIa inactivated by FFR cmk).

The term "TF agonist", as used herein is intended to mean any compound reducing or inhibiting apoptosis of a cell population as determined in the apoptosis assay described in example 3 by direct binding to TF (e.g. FVIIa) or other TF dependent mechanism.

In one embodiment of the invention, the TF agonist is recombinant factor VIIa. In a further embodiment the TF agonist is recombinant human factor VIIa. In a further embodiment the TF agonist is a factor VIIa equivalents. In one embodiment, the factor VII equivalents are amino acid sequence variants having no more than 20 amino acids replaced,

deleted or inserted compared to wild-type factor VII (i.e., a polypeptide having the amino acid sequence disclosed in U.S. Patent No. 4,784,950). In another embodiment, the factor VIIa variants have no more than 15 amino acids replaced, deleted or inserted; in another embodiment, the factor VII variants have no more than 10 amino acids replaced, deleted or inserted; in another embodiment, the factor VII variants have no more than 8 amino acids replaced, deleted or inserted; in another embodiment, the factor VII variants have no more than 6 amino acids replaced, deleted or inserted; in another embodiment, the factor VII variants have no more than 5 amino acids replaced, deleted or inserted; in another embodiment, the factor VIIa variants have no more than 3 amino acids replaced, deleted or inserted compared to wild-type factor VII. In one embodiment, the factor VIIa variants are selected from the list of L305V-FVIIa, L305V/M306D/D309S-FVIIa, L305I-FVIIa, L305T-FVIIa, F374P-FVIIa, V158T/M298Q-FVIIa, V158D/E296V/M298Q-FVIIa, K337A-FVIIa, M298Q-FVIIa, V158D/M298Q-FVIIa, L305V/K337A-FVIIa, V158D/E296V/M298Q/L305V-FVIIa, V158D/E296V/M298Q/K337A-FVIIa, V158D/E296V/M298Q/L305V/K337A-FVIIa, K157A-FVIIa, E296V-FVIIa, E296V/M298Q-FVIIa, V158D/E296V-FVIIa, V158D/M298K-FVIIa, and S336G-FVIIa.

In the present context the three-letter or one-letter indications of the amino acids have been used in their conventional meaning as indicated in table 1. Unless indicated explicitly, the amino acids mentioned herein are L-amino acids. The terminology for factor VIIa variants with amino acid substitutions are as follows. The first letter represent by the one-letter code the amino acid naturally present at a position of human wild-type factor VIIa. The following number represent the position in human wild-type factor VIIa. The second letter represent by the one-letter code the different amino acid substituting for the natural amino acid. An example is L305V/K337A-FVII, the leucine at position 305 of wild-type factor VIIa is replaced by a valine and the Lysine at position 337 of human wild-type factor VIIa is replaced by an alanine, both mutations in the same Factor VII variant.



**Table 1: Abbreviations for amino acids:**

Amino acid	Tree-letter code	One-letter code
Glycine	Gly	G
Proline	Pro	P
Alanine	Ala	A
Valine	Val	V
Leucine	Leu	L
Isoleucine	Ile	I
Methionine	Met	M
Cysteine	Cys	C
Phenylalanine	Phe	F
Tyrosine	Tyr	Y
Tryptophan	Trp	W
Histidine	His	H
Lysine	Lys	K
Arginine	Arg	R
Glutamine	Gln	Q
Asparagine	Asn	N
Glutamic Acid	Glu	E
Aspartic Acid	Asp	D
Serine	Ser	S
Threonine	Thr	T

The term "TF antagonist", as used herein is intended to mean any compound binding directly to TF without reducing or inhibiting apoptosis of a cell population as determined in the apoptosis assay described in example 3 (e.g. FVIIai).

In one embodiment of the invention, the TF antagonist is an antibody against human TF. In one embodiment the antibody is a human antibody. In a further embodiment the antibody is monoclonal antibody. In a further embodiment the antibody is a Fab fragment, F(ab)<sub>2</sub> fragment, F(ab')<sub>2</sub> fragment, or a single chain Fv fragment.

In this context, the term "treatment" is meant to include both prevention of an adverse condition and regulation of an already occurring condition with the purpose of inhibiting or minimising the condition. Prophylactic administration of FVIIa or another TF agonist, or FVIIai or another TF antagonist is thus included in the term "treatment". In this context, the term "patient" is defined as any animal, in particular mammals, such as humans. The term "subject" is used interchangeably with "patient".

Conditions, which may be treated, comprises pathological conditions such as, for example, various cancers, various degenerative neurological disorders, neuropathologies including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), denervation atrophy, otosclerosis, stroke, dementia, multiple sclerosis, Huntington's disease and the encephalopathy associated with acquired immunodeficiency disease (AIDS). In tissues such as skin and intestine, which are turned-over continually during the life of an organism, the cells forming these tissues undergo programmed cell death throughout the life of the or-

ganism. Normally, this process is tightly regulated and the number of cells produced due to cell division is balanced by the number of cells undergoing programmed cell death. However, the regulation of programmed cell death is a complex process involving numerous pathways and, on occasion, defects occur in the regulation of programmed cell death. Given the critical  
5 role of this process in maintaining a steady-state number of cells in a tissue or in maintaining the appropriate cells during development of an organism, defects in programmed cell death often are associated with pathologic conditions.

Various disease states occur due to aberrant regulation of programmed cell death in an organism. For example, defects that result in a decreased level of apoptosis in a tissue as  
10 compared to the normal level required to maintain the steady-state of the tissue can result in an increased number of cells in the tissue. Such a mechanism of increasing cell numbers has been identified in various cancers, where the formation of a tumor occurs not because the cancer cells necessarily are dividing more rapidly than their normal counterparts, but because the cells are not dying at their normal rate. In comparison to cancer, where the likeli-  
15 hood of a cell undergoing apoptosis is decreased, various pathologies are associated with tissues containing cells undergoing a higher than normal amount of apoptosis. For example, increased levels of apoptosis are observed in various neuropathologies, including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), denervation atrophy, otosclerosis, stroke, dementia, multiple sclerosis, Huntington's disease and the encephalopa-  
20 thy associated with acquired immunodeficiency disease (AIDS). Since nerve cells generally do not divide in adults and, therefore, new cells are not available to replace the dying cells, the nerve cell death occurring in such diseases results in the progressively deteriorating condition of patients suffering from the disease. Other conditions associated with a higher than normal level of apoptosis, which may be treated with a TF agonist, comprises myopathies  
25 and muscular dystrophies, glomerulosclerosis, Monckeberg's medial sclerosis, inflammatory bowel disease, Crohn disease, autoimmune hepatitis, hemochromatosis and Wilson disease, viral hepatitis, alcoholic hepatitis, acute hepatic failure of different etiology, diseases of the bile ducts, atherosclerosis, hypertension and apoptosis associated with the use of chemotherapeutic drugs.

30 In a first aspect, the invention relates to a method for reducing or inhibiting apoptosis of a cell population, comprising the step of contacting said cells with a tissue factor agonist. In one embodiment the cells are human cells expressing tissue factor, including fibroblasts, smooth muscle cells, tumour cells, haematopoietic cells, monocytes, macrophages, epithelial cells, keratinocytes, nerve cells and endothelial cells.

In a second aspect, the invention relates to a method for inducing or enhancing apoptosis of a cell population, comprising the step of contacting said cells with a tissue factor antagonist. In one embodiment the cells are human cells expressing tissue factor, including fibroblasts, smooth muscle cells, tumour cells, haematopoietic cells, monocytes, macrophages, epithelial cells, keratinocytes, nerve cells and endothelial cells.

In a further aspect, the invention relates to a method of reducing the severity of a condition in an individual characterized by an elevated level of apoptosis by inhibiting or reducing the level of apoptosis of a cell population, the method comprising administering to the individual an effective amount of a pharmaceutical composition comprising Factor VIIa or factor VII or another tissue factor agonist. In one embodiment of the invention the condition characterized by an elevated level of apoptosis is a neurodegenerative disease. In a further embodiment of the invention the disease or condition characterized by an elevated level of apoptosis is selected from the group consisting of Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), denervation atrophy, otosclerosis, stroke, dementia, multiple sclerosis, Huntington's disease and the encephalopathy associated with acquired immunodeficiency disease (AIDS), myopathies and muscular dystrophies, glomerulosclerosis, Monckeberg's medial sclerosis, inflammatory bowel disease, Crohn disease, autoimmune hepatitis, hemochromatosis and Wilson disease, viral hepatitis, alcoholic hepatitis, acute hepatic failure of different etiology, diseases of the bile ducts, atherosclerosis, hypertension, apoptosis induced hair loss and apoptosis associated with the use of chemotherapeutic drugs. In one embodiment the apoptosis associated with the use of chemotherapeutic drugs results in hair loss.

In a further aspect, the invention relates to a method of reducing the severity of a condition in an individual characterized by a reduced level of apoptosis by inducing or enhancing the level of apoptosis of a cell population, the method comprising administering to the individual an effective amount of a pharmaceutical composition comprising a tissue factor antagonist. In one embodiment of the invention the disease or condition characterized by a reduced level of apoptosis is selected from the group consisting of primary tumour growth, tumour invasion, metastasis, psoriasis, an autoimmune disease and restenosis.

In a further aspect, the invention relates to the use of a tissue factor agonist for the manufacture of a medicament for treatment of disease or condition associated with undesired apoptosis of a cell population.

In a further aspect, the invention relates to the use of a tissue factor antagonist for the manufacture of a medicament for treatment of disease or condition, where induction or enhancement of apoptosis of a cell population is desired.



In a further aspect, the invention relates to a method of regulating apoptosis of a cell population, comprising the step of either contacting said cells with a tissue factor agonist or contacting said cells with a tissue factor antagonist.

In one embodiment of the invention the tissue factor agonist is FVII or FVIIa.

5 In a further embodiment of the invention the tissue factor antagonist is modified FVII. In one embodiment the modified factor VII is selected from factor VII modified with Phe-Phe-Arg chloromethyl ketone, Phe-Phe-Arg chloromethylketone, D-Phe-Phe-Arg chloromethyl ketone, D-Phe-Phe-Arg chloromethylketone Phe-Pro-Arg chloromethylketone, D-Phe-Pro-Arg chloromethylketone, Phe-Pro-Arg chloromethylketone, D-Phe-Pro-Arg chloromethylketone, L-Glu-Gly-Arg chloromethylketone and D-Glu-Gly-Arg chloromethylketone, Dansyl-Phe-Phe-Arg chloromethyl ketone, Dansyl-Phe-Phe-Arg chloromethylketone, Dansyl-D-Phe-Phe-Arg chloromethyl ketone, Dansyl-D-Phe-Phe-Arg chloromethylketone, Dansyl-Phe-Pro-Arg chloromethylketone, Dansyl-D-Phe-Pro-Arg chloromethylketone, Dansyl-Phe-Pro-Arg chloromethylketone, Dansyl-D-Phe-Pro-Arg chloromethylketone, Dansyl-L-Glu-Gly-Arg chloromethylketone and Dansyl-D-Glu-Gly-Arg chloromethylketone.

In another aspect, the present invention relates to a method of detecting drug candidates that regulate apoptosis of a cell population, which method comprise

- a) culturing a TF expressing cells;
- b) measuring the apoptosis of a cell population;
- 20 c) incubating the cells with a drug candidate, and
- d) measuring the apoptosis of the incubated cells and determining any change in the level of apoptosis compared to the level of apoptosis measured in step b, such change being indicative of biologically active drug candidate in said cell.

The term "TF expressing cell" means any mammalian cell that expresses TF.

25 The term "drug candidate" is intended to indicate any sample, which has a biological function or exerts a biological effect in a cellular system. The sample may be a sample of a biological material such as a microbial or plant extract, or it may be a sample containing a compound or mixture of compounds prepared by organic synthesis or genetic techniques.

In a further aspect, the invention relates to the use of tissue factor for the protection  
30 of cells from apoptosis. As can be seen from the experiments disclosed by the present inventors only cells expressing TF are protected from apoptosis. Thus, in a further aspect, the present invention relates to a method of producing a recombinant protein, the method comprising:

- a) transfection of a cell with a polynucleotide constructs encoding TF;

- b) transfection of the same cell with a polynucleotide constructs encoding the recombinant protein to be produced;
- c) cultivating the cell in an appropriate growth medium under conditions allowing expression of the polynucleotide constructs and recovering the resulting polypeptide from the culture medium.

In one embodiment of the invention, the recombinant protein to be produced is human FVII. In a further embodiment the appropriate growth medium comprises FVIIa.

In a further aspect, the invention relates to a method for reducing or inhibiting apoptosis of a cell population, comprising the step of contacting said cells with an activated coagulation factor.

In a further aspect, the invention relates to a method for reducing or inhibiting apoptosis of a cell population, comprising the step of contacting said cells with thrombin or coagulation factor Xa.

In a further aspect, the invention relates to a method for inducing or enhancing apoptosis of a cell population, comprising the step of contacting said cells with a thrombin inhibitor or a coagulation factor Xa inhibitor.

In a further aspect, the invention relates to a method of reducing the severity of a condition in an individual characterized by an elevated level of apoptosis by inhibiting or reducing the level of apoptosis of a cell population, the method comprising administering to the individual an effective amount of a pharmaceutical composition comprising thrombin or coagulation factor Xa.

In a further aspect, the invention relates to a method of reducing the severity of a condition in an individual characterized by a reduced level of apoptosis by inducing or enhancing the level of apoptosis of a cell population, the method comprising administering to the individual an effective amount of a pharmaceutical composition comprising a thrombin inhibitor or a coagulation factor Xa inhibitor.

In a further aspect, the invention relates to the use of thrombin or coagulation factor Xa for the manufacture of a medicament for treatment of disease or condition associated with undesired apoptosis of a cell population.

In a further aspect, the invention relates to the use of a thrombin inhibitor or a coagulation factor Xa inhibitor for the manufacture of a medicament for treatment of disease or condition, where induction or enhancement of apoptosis of a cell population is desired.

In a further aspect, the invention relates to a method of regulating apoptosis of a cell population, comprising the step of either contacting said cells with thrombin or coagulation factor Xa or contacting said cells with a thrombin inhibitor or a coagulation factor Xa inhibitor.

In one embodiment of the present invention the thrombin inhibitor is hirudin. In another embodiment of the present invention the coagulation factor Xa inhibitor is Tick Anticoagulant Protein (TAP). In a specific embodiment the Tick Anticoagulant Protein is a recombinant human protein.

5

#### Abbreviations:

TF	tissue factor
FVII	factor VII in its single-chain, unactivated form
FVIIa	factor VII in its activated form
rFVIIa	recombinant factor VII in its activated form
FVIIai	modified (inactivated) factor VII
FFR-FVIIai	factor VII inactivated by reaction with D-Phe-L-Phe-L-Arg chloromethyl ketone

Tissue factor (TF) is the cellular receptor for factor FVIIa (FVIIa) and the complex is principal initiator of blood coagulation. We have studied the effects of FVIIa binding to TF on cell apoptosis of cells that express high amounts of TF. TF expressing cells incubated with FVIIa is shown to be less sensitive to apoptosis.

Below we show for the first time a clear connection between FVIIa binding to TF and the cell apoptosis. We present data that FVIIa stimulation of TF expressing cells leads to a reduction or inhibition of apoptosis of a cell population. Furthermore, active site-inhibited FVIIa (FFR-FVIIa) is shown to induce or enhance apoptosis of a cell population. TF is constitutively expressed on the plasma membrane of many extravascular cells, such as stromal fibroblasts in vascular adventitia and in fibrous capsules of liver, spleen and kidney. Thus, expression of TF is found at sites physically separated from the circulating blood and providing a haemostatic envelope. Upon injury this barrier is thought to protect the organism against bleeding. TF can, however, be induced in monocytes/macrophages, vascular smooth muscle cells, endothelial cells and in a number of tumour cells by a variety of agents, including cytokines and growth factors. Induction at the transcriptional level occurs rapidly after stimulation, identifying TF as a growth-related immediate early gene.

Not only binding to TF, but also the catalytic activity of TF/FVIIa seem to be mandatory, since active-site inhibited FVIIa did not elicit the protection from apoptosis. We excluded that the protection from apoptosis by FVIIa occurred due to FXa or thrombin, since TAP and Hirudin did not abolish the effect of FVIIa in the apoptosis assay. A dose-response of the anti-apoptotic effect of FVIIa was seen in BHK cells transfected with TF.

The regimen for any patient to be treated with FVIIa or another TF agonist or FVIIai or another TF antagonist as mentioned herein should be determined by those skilled in the art.

5 The daily dose to be administered in therapy can be determined by a physician and will depend on the particular compound employed, on the route of administration and on the weight and the condition of the patient. An effective amount is suitably a daily dosage from about 5 µg/kg/day to about 500 µg/kg/day, preferably from about 10 µg/kg/day to 300 µg/kg/day, more preferred from about 15 µg/kg/day to 200 µg/kg/day, most preferred from about 20 µg/kg/day to 100 µg/kg/day.

10 The FVIIa or another TF agonist or FVIIai or another TF antagonist should be administered in one single dose, but it can also be given in multiple doses preferably with intervals of 4-6-12 hours depending on the dose given and the condition of the patient.

In a particular embodiment the effective amount is a daily dosage from about 5 µg/kg/day to about 500 µg/kg/day of FVIIa or another TF agonist or FVIIai or another TF antagonist.

15 The FVIIa or another TF agonist or FVIIai or another TF antagonist may be administered intravenously or it may be administered by continuous or pulsatile infusion or it may be administered directly to the relevant site such as, for example, injected directly into a tumour. FVIIa or another TF agonist or FVIIai or another TF antagonist is preferably administered by intravenous injections and in an amount of about 100-100,000 units per kg body weight, and  
20 preferably in an amount of about 250 - 25,000 units per kg body weight corresponding to about 5-500 µg/kg, a dose that may have to be repeated 2-4 times per 24 hours.

Conventional techniques for preparing pharmaceutical compositions, which can be used according to the present invention are, for example, described in Remington's Pharmaceutical Sciences, 1985.

25 The compositions used according to this invention are prepared by methods known per se by the skilled artisan.

In short, pharmaceutical preparations suitable for use according to the present invention is made by mixing FVII, FVIIa or another TF agonist or FVIIai or another TF antagonist, preferably in purified form, with suitable adjuvants and a suitable carrier or diluent.  
30 Suitable physiological acceptable carriers or diluents include sterile water and saline. Suitable adjuvants, in this regard, include calcium, proteins (e.g. albumins), or other inert peptides (e.g. glycylglycine) or amino acids (e.g. glycine, or histidine) to stabilise the purified factor VIIa. Other physiological acceptable adjuvants are non-reducing sugars, polyalcohols (e.g. sorbitol, mannitol or glycerol), polysaccharides such as low molecular weight dextrans, detergents (e.g. polysorbate) and antioxidants (e.g. bisulfite and ascorbate). The adjuvants are generally present  
35

in a concentration of from 0.001 to 4% w/v. The pharmaceutical preparation may also contain protease inhibitors, e.g. apronitin, and preserving agents.

The preparations may be sterilised by, for example, filtration through a bacteria-retaining filter, by incorporating sterilising agents into the compositions, by irradiating the compositions, or by heating the compositions. They can also be manufactured in the form of sterile solid compositions, which can be dissolved in sterile water, or some other sterile medium suitable for injection prior to or immediately before use.

The present invention is further illustrated by the following examples that, however, are not to be construed as limiting the scope of protection. The features disclosed in the foregoing description and in the following examples may, both separately and in any combination thereof, be material for realising the invention in diverse forms thereof.

## BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1: Apoptosis illustrated by FITC-dUTP staining of BHK(+TF). Dose-response of FVIIa.

Figure 2: Apoptosis illustrated by FITC-dUTP staining of BHK wt. Dose-response of FVIIa.

Figure 3: Apoptosis illustrated by FITC-dUTP staining of BHK(+TF). Involvement of FXa and thrombin inhibitors.

Figure 4: Apoptosis illustrated by FITC-dUTP staining of BHK wt. Involvement of FXa and thrombin inhibitors.

Figure 5: Apoptosis illustrated by FITC-dUTP staining of BHK(+TF). Effect of FVIIa and FFR-FVIIa on serum-starvation induced apoptosis.

Figure 6: Apoptosis illustrated by FITC-dUTP staining of BHK(+TF). Time-dependency of serum-starvation induced apoptosis.

Figure 7: Apoptosis illustrated by Hoechst staining of condensed nuclei (marked with an arrow) in BHK(+TF) cells.



Figure 8: Apoptosis illustrated by FITC-dUTP staining. Dose-dependent anti-apoptotic effect of FVIIa in cells expressing TF. TUNEL analysis by flow cytometry.

Figure 9: Apoptosis illustrated by FITC-dUTP staining of BHK(+TF) analyzed by TUNEL and flow cytometry. Involvement of FFR-FVIIa. Involvement of FXa and thrombin inhibitors

Figure 10: Time-dependent activation of caspase 3 upon serum deprivation of BHK(+TF) cells. Western blot analysis using anti-caspase 3 ab's. FVIIa show anti-apoptotic effect at all times tested.

Figure 11: Apoptosis illustrated by activation of caspase 3. Western blot analysis using anti-caspase 3 ab's. Anti-apoptotic effect of FVIIa only in cells expressing TF.

Figure 12: Apoptosis illustrated by Caspase 3 activation in CHO cells. Western blot analysis using anti-caspase 3 ab's. Effect of FVIIa only in cells expressing TF.

Figure 13: The anti-apoptotic effect of FVIIa is dose-dependent and correlates with the ability of FVIIa to activate p44/42 MAPK and Akt in BHK(+TF) cells. Western blot analysis.

Figure 14: Apoptosis illustrated by wb analysis of activated caspase 3 in BHK(+TF) cells. Preventing FVIIa from binding to TF neutralizes the anti-apoptotic effect of FVIIa.

## EXAMPLES

### Example 1

#### Preparation of FVII

Human purified factor VIIa suitable for use in the present invention is preferably made by DNA recombinant technology, e.g. as described by Hagen et al., Proc.Natl.Acad.Sci. USA 83: 2412-2416, 1986 or as described in European Patent No. 200.421 (ZymoGenetics). Factor VIIa produced by recombinant technology may be authentic factor VIIa or a more or less modified factor VIIa provided that such factor VIIa has substantially the same biological activity for

blood coagulation as authentic factor VIIa. Such modified factor VIIa may be produced by modifying the nucleic acid sequence encoding factor VII either by altering the amino acid codons or by removal of some of the amino acid codons in the nucleic acid encoding the natural FVII by known means, e.g. by site-specific mutagenesis.

5           Factor VII may also be produced by the methods described by Broze and Majerus, J.Biol.Chem. 255 (4): 1242-1247, 1980 and Hedner and Kisiel, J.Clin.Invest. 71: 1836-1841, 1983. These methods yield factor VII without detectable amounts of other blood coagulation factors. An even further purified factor VII preparation may be obtained by including an additional gel filtration as the final purification step. Factor VII is then converted into activated FVIIa  
10 by known means, e.g. by several different plasma proteins, such as factor XIIa, IX a or Xa. Alternatively, as described by Bjoern et al. (Research Disclosure, 269 September 1986, pp. 564-565), factor VII may be activated by passing it through an ion-exchange chromatography column, such as Mono Q® (Pharmacia fine Chemicals) or the like.

## 15   **Example 2**

### Preparation of FVIIa

Modified factor VII suitable for use in the present invention is made, e.g. as described in International Publications Nos. 92/15686, 94/27631, 96/12800 and 97/47651 ZymoGenet-  
20 ics/Novo Nordisk).

## **Example 3**

To investigate the effect of FVIIa on BHK(+TF) and BHK wt cell survival, apoptosis  
25 of cells was induced by serum-starvation for 24 hr and 48 hr. Apoptosis was detected by flow cytometry after Terminal deoxynucleotidyl-transferase dUTP Nick End Labelling (TUNEL). One of the later steps in apoptosis is DNA fragmentation, a process which results from the activation of endonucleases during the apoptotic program. The nucleases degrade the higher order chromatin structure into fragments of approximately 300 kb and subsequently into  
30 smaller DNA pieces about 50 bp length. In the TUNEL assay (APO-BRDU from Pharmingen) TdT catalyses a template-independent addition of brominated deoxyuridine triphosphates (Br-dUTP) to the 3'-hydroxyl termini of double- and single-stranded DNA in paraformaldehyde and ethanol fixed cells. After incorporation these sites are identified by flow cytometric means by staining the cells with a FITC-labelled anti-BrdU mAb. To follow cell-cycle pro-  
35 gress, the cells are in the final step labelled with Propidium Iodine (PI).

Proteins - Human recombinant FVII and FVIIa was expressed and purified as described by Thim, L. et al. Biochem 27: 7785-7793, 1988.

FVIIai was obtained by blocking of FVIIa in the active site with D-Phe-L-Phe-L-Arg chloromethyl ketone (FFR-FVIIa) as previously described by Sorensen B. B. et al. J.Biol.Chem. 272: 11863-11868, 1997.

Thrombin was from Enzyme Research Lab. The specific thrombin inhibitor hirudin may be purchased from Sigma-Aldrich and the specific FXa inhibitor Recombinant TAP (Tick Anticoagulant Protein) was kindly provided by Dr. G. P. Vlasuk, Corvas (San Diego, CA). Cell Culture - The baby hamster kidney cell line BHK-21 tk- ts13 (ATCC CRL 1632) was cultured in Dulbecco's modified Eagle's medium containing 10% FCS, 100 IU/ml penicillin, 100 µg/ml streptomycin. All cell lines were grown in T80 or T175 flasks and subcultured into 10 cm single culture dishes (78 cm<sup>2</sup>).

Transfection of BHK cells with TF -The complete human TF cDNA was cloned into the mammalian Zem219b expression vector. BHK cells were transfected with the TF expression plasmid using the calcium phosphate coprecipitation standard technique. Cells with stably integrated constructs were selected with 1 µM Methotrexate.

#### Experimental:

The cells were seeded (800.000 cells/dish) in DMEM supplemented with 10% FCS, 100 IU/ml penicillin, 100 µg/ml streptomycin (DMEM+/+). After two days the cells were approximately 80% confluent and ready for serum-starvation. The cells were washed two times with DMEM -/- media (before use DMEM -/- was left in the incubator over night for right pH stabilization and temperature) and after the final wash cells were left with 6 ml DMEM-/- and the indicated compounds for 24 hr and/or 48 hr. At the end of the incubation period the loose cells in the media was pooled with the trypsin-treated adhered cells and centrifugated at 300xg for 5 min. Cells were washed with PBS before fixation in 1% paraformaldehyde in PBS on ice for 15 min. Hereafter cells were washed in PBS and resuspended in 500 µl PBS before addition of 5 ml 70% EtOH. The cell-suspension was left for at least 18 hr at -20°C before analysed by TUNEL assay accordingly to the manufactures procedures (Apo-BRDU from Pharmingen).

**Results:**

Dose-response of the anti-apoptotic effect of FVIIa in BHK(+TF) and BHK wt cells. In BHK(+TF) cells apoptosis was induced by serum-starvation for 24 hr or 48 hr and apoptotic cells were detected by TUNEL staining and flow cytometry. The results are presented as FITC-labelled DNA-breaks (FITC-dUTP) on a log x-scale (the more right shift in the x-axis value the more DNA-breaks in the cell) and the y-axis depicts cell number on a linearly scale. BHK(+TF) cells were serum-starved in the presence of increasing concentrations of FVIIa (from 12.5 nM to 100 nM). When BHK(+TF) cells was left for 24 hr in serum-deprived media a clear increase in the number of apoptotic cells (Fig. 1A) was seen as a decrease in the peak representing healthy cells (10% serum) grown in the presence of 10% serum. The remaining four curves in Fig. 1A represent increasing concentration of FVIIa, and the results show that as low concentration as 12.5 nM FVIIa was able to rescue the cell population from apoptosis. In Fig. 1B BHK(+TF) cells were keep in serum-deprived media for 48 hr with increasing concentration of FVIIa. In this experiment there was a very clear increase in apoptotic cells seen by comparing non-treated with 10% serum treated cells. After 48 hr the non-treated cells were more apoptotic than after 24 hr serum-deprivation. A very clear dose-dependent inhibition of apoptosis was seen with FVIIa after 48 hr serum-starvation. At 100 nM FVIIa almost total suppression of apoptosis was seen.

**Effect of TAP and hirudin on FVIIa induced inhibition of apoptosis**

Since a significant effect of FVIIa was seen in this assays, it was important to determine if this apoptosis-suppressive effect is specific to FVIIa or if down-stream coagulation products could account for these findings. Therefore BHK(+TF) cells were serum-starved for 24 hr or 48 hr in the presence of FVIIa (100 nM) with or without the specific thrombin inhibitor hirudin (25 U/ml) and the specific FXa inhibitor TAP(100 nM). As a control thrombin (10 nM) with or without hirudin + TAP was also tested. Fig. 3A show that non-treated cells at 24 hr serum-deprivation resulted apoptotic cells by a decreased in FITC-dUTP "healthy peak" and a slight right-shift of the peak compared to healthy serum-treated cells represented by the black line. Here FVIIa showed totally inhibition of apoptosis and this effect is not influenced by addition of hirudin and TAP, indicating that FXa and FIIa are not involved in the FVIIa induced protection from apoptosis. As a control experiment cells were serum-starved in the presence of 10 nM FIIa. FIIa was to the same extend as FVIIa able to inhibit apoptosis. By adding FIIa and hirudin + TAP simultaneously this inhibition of apoptosis is abolished and the cells show clearly increase in apoptotic cells by right-shift in FITC-dUTP, resulting in an extra peak. At 48 hr of serum-starvation the non-treated (Fig. 3B) cells are more apoptotic compared to 24

hr serum-starvation. In this experiment FVIIa independently of hirudin and TAP partly inhibited apoptosis. The same degree of apoptosis-inhibition was seen with FIIa. A concentration of 10 nM FVIIa (Fig. 3B) was not enough to inhibit apoptosis during 48 hr serum-starvation. In conclusion both at 24 hr and 48 hr of serum-starvation FVIIa's anti-apoptotic effect is independent of the down-stream coagulation products FXa and FIIa.

BHK wt cells were also investigated in the same experiment exploring the effect of specific inhibitors of down-stream coagulation products on the anti-apoptotic effect of FVIIa. When BHK wt cells were serum-starved for 24 hr there was no increase in apoptotic cells (Fig. 4A) compared to 10%-treated cells and this correlates well with the experiment shown in Fig. 2A. Serum-starvation for 48 hr of BHK wt cells (Fig. 4B) clearly resulted in an increase in apoptotic cells compare to healthy cells (Fig. 4B). In this experiment FVIIa at 100 nM with or without hirudin and TAP and FVIIa at 10 nM had no anti-apoptotic effect (Fig. 4B). It was very clear that FIIa showed the same anti-apoptotic effect on BHK wt cells (Fig. 4B) as on BHK(+TF) cells (Fig. 3B).

Proteolytic activity of FVIIa is mandatory for the anti-apoptotic effect.

In order to investigate if binding of FVIIa to TF was enough to induce this anti-apoptotic effect an active site-inactivated variant of FVIIa (FFR-FVIIa) was added to the cells during the starvation period. FFR-FVIIa binds with a two fold higher affinity to TF but leaves the complex proteolytically inactive. Fig. 5 depicts an experiment employing BHK(+TF) cells where FVIIa at both 24 hr (Fig. 5A) and 48 hr (Fig. 5B) serum-starvation had a clear apoptosis-suppressive effect. Interestingly FFR-FVIIa (Fig. 5C) was not able to rescue any cells and the population of cells was identical to non-treated cells both at 24 hr and 48 hr of serum-deprivation.

Time-dependency of serum-starvation induced apoptosis in BHK(+TF) cells.

TUNEL staining of apoptotic cells will only detect late-stage apoptosis since DNA-breaks must be formed. BHK(+TF) cells were serum-starved for 17, 22, and 44 hr with or without FVIIa and FFR-FVIIa. In the experiment 10% serum was employed as control of healthy cells and no-treatment as an apoptosis-positive control. From Fig. 6 it is seen that 22 hr (panel B) of serum-starvation was minimum time to induce measurable apoptosis by labelling DNA-breaks with the TUNEL assay. When the cells were grown for 17 hr (panel A) in serum-deprived media no significant amount of apoptosis was seen. In contrast 44 hr of serum-



starvation very clearly induced apoptosis in this assay. From Fig. 6 it is also clear that FVIIa but not FFR-FVIIa show anti-apoptotic effects after 44 hr of serum-deprivation.

#### Example 4

5           Recombinant human FVIIa and FFR-FVIIa were prepared as described in example 1 and 2. Factors X, FXa, thrombin and hirudin were obtained from Enzyme Research Laboratories (South Bend, IN). The specific FXa inhibitor, recombinant tick anticoagulant protein (TAP), was a generous gift from Dr. Vlasuk (Corvas, La Jolla, CA). Antibodies against cas-  
pase 3, phosphorylated p44/42 MAPK, and phosphorylated Akt were from Cell Signaling  
10   Technology (Boston, MA).  $\beta$ -actin antibody was from Abcam (Cambridge, UK). LY294002 and U0126 were from Promega (Madison, WI).

*Cell lines* - The Baby Hamster Kidney cell line BHK-21 tk<sup>-</sup> (ATCC CRL1632) was cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% FCS, 100 IU/ml penicillin, 100  $\mu$ g/ml streptomycin. The complete human TF cDNA was cloned into the  
15   mammalian Zem219b expression vector and transfected into BHK cells using the calcium phosphate coprecipitation procedure and stably integrated constructs were selected using 1  $\mu$ M methotrexate (Sorensen, B. B., Freskgard, P.-O., Nielsen, L. S., Rao, L. V. M., Ezban, M., and Petersen, L. C. (1999) J.Biol.Chem. 274, 21349-21354). Chinese hamster ovary (CHO-K1, ATCC CCL-61) cells were cultured in Ham-F12 medium supplemented with 10%  
20   FCS and 1% non-essential amino acids. CHO cells were transfected with the complete human TF in the pcDNA3 (Invitrogen, Carlsbad, CA) using FuGene<sup>TM</sup> (Roche Diagnostics, Indianapolis, IN). Stable cell lines were selected by resistance to geneticin (0.7 mg/ml). Clonal cell lines were tested for TF expression in a FXa generation assay employing intact monolayers of cells. The expression of functional TF in the two transfected cell lines  
25   BHK(+TF) and CHO(+TF) were comparable as judged by the FXa generation assay.

*TUNEL/flow cytometry*- The cells were seeded in 9 cm dishes (800,000 cells/dish) in DMEM supplemented with 10% FCS, 100 IU/ml penicillin, 100  $\mu$ g/ml streptomycin. When cells were approximately 80% confluent, they were subjected to serum deprivation in the presence and absence of experimental compounds. Briefly, the monolayers were washed  
30   twice with DMEM (before use the DMEM was left in the incubator over night for pH stabilization) and after the final wash the cells were overlaid with 6 ml DMEM containing the experimental test compounds for 24 or 48 h. At the end of the incubation period, the loose cells in the media were collected and pooled with the trypsin-detached adhered cells, and centrifuged at 300 x g for 5 min. The cells were washed with PBS before fixation in 1% parafor-  
35   maldehyde in PBS on ice for 15 min. After the fixation, the cells were washed in PBS and

resuspended in 500 µl PBS before adding 5 ml of 70% EtOH. The cell suspension was left for at least 18 h at –20°C before they were analyzed by TUNEL assay (Apo-BRDU, BD Biosciences Pharmingen, San Diego, CA) following the procedure described in manufacturer's technical bulletin. Stained cells were analyzed by a FACScan™ flow cytometer (Becton Dickinson).

*Detection of caspase 3 activation* - Cells were cultured in 9-cm dishes and serum deprived in the presence or absence of experimental test compound as described under TUNEL. At the end of specific time interval, as indicated in Results, the cultured dish was placed on ice and the overlaying medium containing loose cells was collected. The adhered cells were scraped from the bottom of the dish and pooled with the conditioned medium and centrifuged at 300 x g for 5 min at 4°C to obtain the cell pellet. The supernatant was discarded and the tubes were drained carefully (by inverting the tubes) to obtain the cell pellet. The cells were lysed by adding 50 µl of ice-cold Chaps Cell Extract Buffer (50 mM Pipes/KOH, pH 6.5, 2 mM EDTA, 0.1% Chaps, supplemented immediately prior to use with 20 µg/ml Leupeptin, 10 µg/ml aprotinin, 5 mM DTT, 0.1 mM AEBSF (4-(2-Aminoethyl)-bezenesulfonylfluoride)). The lysates were frozen and thawed three times, centrifuged at 15,000 x g for 5 min at 4°C. The supernatant was collected and total protein concentration was determined by Bio-Rad protein assay kit. Approximately 10 µg of protein was subjected to SDS-PAGE on 4-12% gradient gel under reducing conditions. Caspase 3 activation was evaluated by western blot analysis using an antibody against caspase 3 that recognizes both the zymogen (33 kDa) as well as the cleaved antigen (18 kDa).

*Determination of Akt and p44/42 MAP kinase activation* - Cells were seeded in the complete medium in 6-well plates. When the cells reached 80-90 % confluency, the cells were washed twice in serum free medium and left in serum free medium for 2 h to make the cells quiescent. Cells were stimulated with FVIIa for 10 min at 37°C. Where inhibitors were included, they were added to the cells 30 min prior to the addition of FVIIa. After the 10 min treatment with FVIIa, the cells were lysed in Lysis buffer (20 mM Tris, 0.1% (v/w) Triton X-100, 1 mM EDTA, 1 mM EGTA, 50 mM sodium-fluoride, 10 mM sodium β-glycerophosphate, 5 mM sodium pyrophosphate, 0.1 mM AEBSF (4-(2-Aminoethyl)-bezenesulfonylfluoride), 1 mM benzamidine, 150 mM NaCl, pH 7.5. Added just before use: 1 mM sodium orthovanadate, 5 µg/ml leupeptin, 10 µg/ml aprotinin). Ten µg protein was loaded on to SDS-PAGE (4-12% gradient gel, reducing condition) and subjected to western blot analysis using specific antibodies against phosphorylated p44/42 MAPK and cAkt.

*Western blot analysis* – After electroblotting, the membranes were blocked in blocking buffer (TBS containing 0.1% Tween-20 and 5% non-fat dry milk) for 1 h and washed 3

times in TBS with 0.1% Tween-20 (TBS/T) before adding the primary antibody (1:1000, and for  $\beta$ -actin 1:1,000,000) in the blocking buffer. After overnight incubation with the primary antibody at 4°C, the membranes were washed 3 times in TBS/T before adding the HRP-conjugated secondary antibody (1:2000) in the blocking buffer. Membranes were incubated for 1 hr at room temperature before washing thrice with TBS/T. Chemiluminescence substrate (Supersignal, Pierce) was added for 5 min and the chemiluminescence was detected by a cooled CCD-camera (LAS1000, Fujifilm). These digital images were used to quantify the intensity of the bands using Image Gauge v. 4.0 (Fujifilm).

*Immunocytochemistry* - BHK(+TF) cells were seeded in 8-chamber glass slides (Nalge Nunc International, Rochester, NY) and grown to 30% confluence. Cells were washed and incubated with serum free medium supplemented with none, 20 nM FVIIa, 20 nM FFR-FVIIa, or 10% FCS for 6 hr. At the end of the experiment cells were washed, fixed in 4% (v/v) paraformaldehyde in phosphate-buffered saline (PBS) for 15 min. at 4°C, briefly rinsed in PBS, post-fixed in 70% (v/v) ethanol for 15 min at RT, and air-dried. Antigen retrieval was achieved by microwave oven (Polar Patent, Umeå, Sweden) pre-treatment in 10 mM citrate buffer pH 6.0 preheated to 60°C for 3 x 5 min at 80% effect. The cells were cooled for 10 min in the citrate buffer at room temperature, rinsed in Tris-buffered saline (TBS), pre-incubated for 15 minutes in 5% donkey serum in TBS, followed by incubation with goat anti-human TF IgG (American Diagnostica Incorporation, Greenwich, Ct) overnight at 4 °C. The cells were then incubated with biotinylated donkey anti-goat (Jackson ImmunoResearch Laboratory, West Grove, PE) for 1 hr, HRP-streptavidin (NEN Life Science Products, Boston, MA) for 30 min, and TSA-FITC (Tyramide Signal Amplification Fluorescein system) (NEN Life Science Products, Boston, MA). Following a brief rinse in TBS the cells were counterstained with Hoechst (Molecular Probes, Leiden, The Netherlands) for morphological analyses of apoptotic cells, rinsed in H<sub>2</sub>O and mounted with Mounting Medium Fluorescence (DAKO, Glostrup, Denmark). The cells were photographed using an Olympus BX51 reflected fluorescence system microscope equipped with selective AMCA and FITCH filters, and, a DP50 digital camera.

#### *Results:*

FVIIa prevents nuclei chromatin condensation under serum-free conditions. The inventors of the present invention have found out, that upon serum-deprivation, BHK(+TF) cells tend to round up, loosely adhere to culture dishes (detach easily from the dish) and undergo subtle morphological changes. These changes were diminished, when FVIIa was included in serum-free medium. The present invention is based on the examined effect of FVIIa and FFR-FVIIa on cell viability and apoptosis, where cells were examined for apoptotic morphol-

ogy changes. Under serum-starvation conditions (Fig. 7, panels A and B), fluorescence microscopy revealed that a considerable number of BHK(+TF) cells were characterized by apoptotic blebs and nuclei with chromatin-condensed bodies, whereas the presence of FVIIa during serum starvation markedly decreased the number of cells with apoptotic morphology (Fig. 7, panels C and D) such that cell cultures exposed to FVIIa had an appearance similar to those maintained in serum containing medium (Fig. 7, panels G and H). In contrast to FVIIa, FFR-FVIIa failed to prevent nuclei condensation induced by serum deprivation (Fig. 7, panels E and F) suggesting that the proteolytic activity of FVIIa was essential for this effect.

Anti-apoptotic effect of FVIIa under serum-deprived conditions – The cell morphology observations in Fig. 7 suggested that exposure of FVIIa to serum starved BHK(+TF) cells produces an anti-apoptotic effect. To obtain a quantitative characterization of this effect we examined the cells for apoptotic changes measuring DNA degradation by means of TUNEL / flow cytometry. Compared to the serum control, culturing of BHK(+TF) cells in serum-free conditions for 24 hr markedly increased the fraction of apoptotic cells with advanced DNA degradation (Fig. 8A) and this fraction was slightly increased with prolonged serum starvation to 48 hr (Fig. 8B). Notably, however, the cells were rescued from apoptosis in a dose dependent manner upon addition of 1 pM to 100 nM FVIIa to the serum-deprived medium. The anti-apoptotic effect of FVIIa was evident at 1 nM with substantially increased cell survival at 10 nM FVIIa; that is at a concentration equivalent to the FVII plasma level. An increase to 100 nM FVIIa slightly improved cell survival further. A similar profile of anti-apoptotic effect of FVIIa was observed in cells exposed to FVIIa for 48 h (Fig. 8B).

Wild-type, non-transfected BHK cells, do not express detectable levels of TF. Like TF-transfected cells, culture of these cells under serum free conditions for 48 hr resulted in extensive apoptosis as demonstrated by the TUNEL assay. However, Fig. 8C shows that in contrast to BHK(+TF) cells, wild-type BHK cells could not be rescued from apoptosis by FVIIa suggesting that binding to TF is essential for its anti-apoptotic effect.

The observation that FVIIa but not active site blocked FVIIa, FFR-FVIIa, was able to preserve BHK(+TF) cells from the morphological changes induced by serum starvation prompted us to explore this further with the TUNEL assay. Next, It was establish that FVIIa proteolytic activity is required for its anti-apoptotic effect. The results shown in Fig. 9A clearly indicated that the activity is essential since FVIIa, but not FFR-FVIIa, protected BHK(+TF) cells from apoptosis.

Like FVIIa, the down-stream proteases of the TF coagulation pathway, FXa and thrombin, are known to induce intracellular signaling producing various cellular responses. It was therefore important to rule out that FVIIa exerted its effect through generation of small



amounts of down-stream coagulation factors. Although we have used recombinant FVIIa in these studies and found no evidence for the generation of FXa or thrombin in our experimental system, we evaluated the anti-apoptotic effect of FVIIa in the presence of specific inhibitors of both FXa and thrombin, i.e., TAP and hirudin, respectively. As shown in Fig. 9B, TAP and hirudin failed to prevent the anti-apoptotic effect of FVIIa whereas they completely abolished the anti-apoptotic effect of FXa and thrombin. These data establishes that the specific protease activity of FVIIa/TF is responsible for the reduction in apoptosis observed in TF expressing cells exposed to FVIIa.

FVIIa suppresses caspase 3 activation – Caspases, a family of cysteine proteases, are central regulators of apoptosis. Caspases are synthesized as latent zymogens organized in cascade systems that upon activation stimulate apoptosis. Inhibition of apoptosis is accomplished either by inhibiting the activity of caspases or by preventing their activation. To obtain clues on the mechanism by which FVIIa inhibits apoptosis, we investigated the activation of the central apoptosis effector, caspase 3, by Western blot analysis using an antibody that recognizes the zymogen as well as the activated enzyme form. Serum removal induced a time-dependent appearance of a 18-20 kDa caspase 3 band in BHK(+TF) cells (Fig. 10). Caspase 3 activation was evident 2 hr after serum deprivation and reached a maximum at 3 hr. The activation was maintained for at least 5 hr (the duration of the experiment). However, the presence of 100 nM FVIIa in the serum free medium clearly attenuated caspase 3 activation with 70-80% at 3, 4, and 5 hr. In additional experiments (data not shown), FVIIa induced a dose-dependent inhibition of caspase 3 activation, which correlated with the dose-dependent inhibition of apoptosis measured in TUNEL assay. In contrast to BHK(+TF) cells, FVIIa failed to inhibit caspase 3 activation in wild type BHK cells that do not express TF (Fig. 11B). Serum abolished the activation of caspase 3 in both BHK(+TF) and wild-type BHK cells. Similar data were obtained with wild type CHO-K1 and TF-transfected CHO cells (Fig. 12).

FVIIa/TF was shown in quiescent BHK(+TF) cells to activate p44/42 MAPK (Fig. 13A) as well as Akt (Fig. 13B), and both are considered important players in survival signaling. However it is currently not clear which kinase is responsible for the anti-apoptotic effect of FVIIa. Experiments with the specific MEK inhibitor U0126 and the specific PI3-kinase inhibitor LY294003 indicates that both kinases might be involved in the anti-apoptotic effect of FVIIa (data not shown).

To verify that the anti-apoptotic effect of FVIIa was mediated through TF, antagonists of FVIIa - TF interaction (FFR-FVIIa and mAb 1F44A1) were preincubated with the cells before addition of FVIIa in serum-free medium. Apoptosis was detected by caspases-3 acti-



vation. FFR-FVIIa and the monoclonal anti-human TF antibody 1F44A1 were able to attenuate the anti-apoptotic effect of FVIIa (Fig. 14).

**CLAIMS**

1. A method for reducing or inhibiting apoptosis of a cell population, comprising the step of contacting said cells with a tissue factor agonist.

5

2. The method according to claim 1, wherein the tissue factor agonist is FVII or FVIIa.

3. A method for inducing or enhancing apoptosis of a cell population, comprising the step of contacting said cells with a tissue factor antagonist.

10

4. The method according to claim 3, wherein the tissue factor antagonist is modified FVII.

5. The method according to any one of the claims 1-4, wherein said cells are a human cells expressing tissue factor, including fibroblasts, smooth muscle cells, tumour cells, haemato-  
poietic cells, monocytes, macrophages, epithelial cells, keratinocytes, nerve cells and  
endothelial cells.

15

6. The method according to claim 4, wherein the modified factor VII is selected from factor VII modified with Phe-Phe-Arg chloromethyl ketone, Phe-Phe-Arg chloromethylketone, D-  
Phe-Phe-Arg chloromethyl ketone, D-Phe-Phe-Arg chloromethylketone Phe-Pro-Arg chloro-  
methylketone, D-Phe-Pro-Arg chloromethylketone, Phe-Pro-Arg chloromethylketone, D-Phe-  
Pro-Arg chloromethylketone, L-Glu-Gly-Arg chloromethylketone and D-Glu-Gly-Arg chloro-  
methylketone, Dansyl-Phe-Phe-Arg chloromethyl ketone, Dansyl-Phe-Phe-Arg chloro-  
methylketone, Dansyl-D-Phe-Phe-Arg chloromethyl ketone, Dansyl-D-Phe-Phe-Arg chloro-  
methylketone, Dansyl-Phe-Pro-Arg chloromethylketone, Dansyl-D-Phe-Pro-Arg chloro-  
methylketone, Dansyl-Phe-Pro-Arg chloromethylketone, Dansyl-D-Phe-Pro-Arg chloro-  
methylketone, Dansyl-L-Glu-Gly-Arg chloromethylketone, and Dansyl-D-Glu-Gly-Arg chloro-  
methylketone.

20

25

7. A method of reducing the severity of a condition in an individual characterized by an elevated level of apoptosis by inhibiting or reducing the level of apoptosis of a cell population, the method comprising administering to the individual an effective amount of a pharmaceutical composition comprising Factor VIIa or factor VII or another tissue factor agonist.

30

35

8. A method of reducing the severity of a condition in an individual characterized by a reduced level of apoptosis by inducing or enhancing the level of apoptosis of a cell population, the method comprising administering to the individual an effective amount of a pharmaceutical composition comprising a tissue factor antagonist.

5

9. The method of claim 7, wherein said condition is selected from the group consisting of neurodegenerative diseases, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), denervation atrophy, otosclerosis, stroke, dementia, multiple sclerosis, Huntington's disease and the encephalopathy associated with acquired immunodeficiency disease (AIDS), myopathies and muscular dystrophies, glomerulosclerosis, Monckeberg's medial sclerosis, inflammatory bowel disease, Crohn disease, autoimmune hepatitis, hemochromatosis and Wilson disease, viral hepatitis, alcoholic hepatitis, acute hepatic failure of different etiology, diseases of the bile ducts, atherosclerosis, hypertension, apoptosis induced hair loss and apoptosis associated with the use of chemotherapeutic drugs.

10

15

10. A method according to claim 8, wherein the disease or condition is selected from the group consisting of primary tumour growth, tumour invasion, metastasis, psoriasis, an autoimmune disease and restenosis.

20

11. A method according to any of claims 8 and 10, wherein the tissue factor antagonist is modified factor VII.

12. Use of a tissue factor agonist for the manufacture of a medicament for treatment of disease or condition associated with undesired apoptosis of a cell population.

25

13. Use according to claim 12, wherein the tissue factor agonist is FVII or FVIIa or a combination thereof.

30

14. Use of a tissue factor antagonist for the manufacture of a medicament for treatment of disease or condition, where induction or enhancement of apoptosis of a cell population is desired.

15. The use of claim 14, wherein the tissue factor antagonist is modified factor VII.

16. Use according to claim 15, wherein the modified factor VII is selected from factor VII modified with Phe-Phe-Arg chloromethyl ketone, Phe-Phe-Arg chloromethylketone, D-Phe-Phe-Arg chloromethyl ketone, D-Phe-Phe-Arg chloromethylketone Phe-Pro-Arg chloromethylketone, D-Phe-Pro-Arg chloromethylketone, Phe-Pro-Arg chloromethylketone, D-Phe-Pro-Arg chloromethylketone, L-Glu-Gly-Arg chloromethylketone and D-Glu-Gly-Arg chloromethylketone, Dansyl-Phe-Phe-Arg chloromethyl ketone, Dansyl-Phe-Phe-Arg chloromethylketone, Dansyl-D-Phe-Phe-Arg chloromethyl ketone, Dansyl-D-Phe-Phe-Arg chloromethylketone, Dansyl-Phe-Pro-Arg chloromethylketone, Dansyl-D-Phe-Pro-Arg chloromethylketone, Dansyl-Phe-Pro-Arg chloromethylketone, Dansyl-D-Phe-Pro-Arg chloromethylketone, Dansyl-L-Glu-Gly-Arg chloromethylketone and Dansyl-D-Glu-Gly-Arg chloromethylketone.

17. A method of regulating apoptosis of a cell population, comprising the step of either contacting said cells with a tissue factor agonist or contacting said cells with a tissue factor antagonist.


18. The method of claim 17, wherein the tissue factor agonist is FVII or FVIIa.

19. The method of claim 18, wherein the tissue factor antagonist is modified FVII.

1/14

Apoptosis illustrated by FITC-dUTP staining of BHK(+TF)  
Dose-response of FVIIa

A Serum-starved for 24 hr with the indicated compounds



B Serum-starved for 48 hr with the indicated compounds





Fig. 1



2/14

Apoptosis illustrated by FITC-dUTP staining of BHK wt  
Dose-response of FVIIa

Serum-starved for 24 hr with the indicated compounds



Serum-starved for 48 hr with the indicated compounds





Fig. 2

3/14

Apoptosis illustrated by FITC-dUTP staining of BHK(+TF)  
Involvement of FXa and thrombin inhibitors

Serum-starved for 24 hr with the indicated compounds



Serum-starved for 48 hr with the indicated compounds





Fig. 3

4/14

Apoptosis illustrated by FITC-dUTP  
staining of BHK wt  
Involvement of FXa and thrombin inhibitors  
Serum-starved for 24 hr with the indicated  
compounds



Serum-starved for 48 hr with the indicated  
compounds





Fig. 4

5/14

Apoptosis illustrated by FITC-dUTP staining of BHK(+TF)  
Effect of FVIIa and FFR-FVIIa on serum-starvation  
induced apoptosis

Serum-starved for 24 hr with the indicated compounds



Serum-starved for 48 hr with the indicated compounds





Fig. 5


6/14

Apoptosis illustrated by FITC-dUTP staining of BHK(+TF)  
Time-dependency of serum-starvation induced apoptosis

A Serum-starved for 17 hr with the indicated compounds



B Serum-starved for 22 hr with the indicated compounds



C Serum-starved for 44 hr with the indicated compounds





Fig. 6



7/14

Apoptosis illustrated by Hoechst staining of condensed nuclei (marked with an arrow) in BHK(+TF) cells.



Identification of apoptotic cells and immunofluorescence staining for TF. BHK(TF) cells deprived of serum for 6 hrs (A,B), were treated with 20 nM rFVIIa (C,D), 20 nM FFR-FVIIa (E,F) or control medium (G,H). Immunofluorescence staining for TF (green FITC signal) are seen in B, D, F and H. Morphological appearance of apoptotic nuclei were visualized by Hoechst staining of the BHK(TF) cells (A, C, E and G). Note the apoptotic cells (arrows) when BHK(TF) cells were deprived of serum (A,B) or treated with FFR-FVIIa (E,F) compared to the inhibition of apoptosis seen by absences of any apoptotic nuclei when treated with FVIIa (C,D) or control medium (G,H). Bar = 50 μm.

Fig. 7

BEST AVAILABLE COPY

8/14

Apoptosis illustrated by FITC-dUTP staining. Dose-dependent anti-apoptotic effect of FVIIa in cells expressing TF. TUNEL analysis by flow cytometry.




Fig. 8

9/14

Apoptosis illustrated by FITC-dUTP staining of BHK(+TF)  
analyzed by TUNEL and flow cytometry.  
Involvement of FFR-FVIIa  
Involvement of FXa and thrombin inhibitors



**A: BHK(+TF), 24 hr****B: BHK(+TF), 24 hr**

Fig. 9

10/14

Time-dependent activation of caspase 3 upon serum deprivation of BHK(+TF) cells. Western blot analysis using anti-caspase 3 ab's. FVIIa show anti-apoptotic effect at all times tested.




Fig. 10

11/14

Apoptosis illustrated by activation of caspase 3.  
Western blot anlysis using anti-caspase 3 ab's.  
Anti-apoptotic effect of FVIIa only in cells  
expressing TF.




Fig. 11



12/14

Apoptosis illustrated by Caspase 3 activation in CHO cells. Western blot analysis using anti-caspase 3 ab's. Effect of FVIIa only in cells expressing TF.




Fig. 12

13/14

The anti-apoptotic effect of FVIIa is dose-dependent and correlates with the ability of FVIIa to activate p44/42 MAPK and Akt in BHK(+TF) cells. Western blot analysis.




Fig. 13

14/14

Apoptosis illustrated by wb analysis of activated caspase 3 in BHK(+TF) cells. Preventing FVIIa from binding to TF neutralizes the anti-apoptotic effect of FVIIa.




Fig. 14

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
8 May 2003 (08.05.2003)

PCT

(10) International Publication Number  
**WO 2003/037361 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 38/48,**  
38/36

(21) International Application Number:  
PCT/DK2002/000727

(22) International Filing Date:  
1 November 2002 (01.11.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
PA 2001 01628 2 November 2001 (02.11.2001) DK

(71) Applicant: **NOVO NORDISK HEALTH CARE AG**  
[DK/CH]; Andreasstrasse 15, CH-8050 Zürich (CH).

(72) Inventors: **SØRENSEN, Brit, Binow**; 1 Mari-  
anelundsvej, DK-3460 Birkerød (DK). **PETERSEN,**  
**Lars, Christian**; 4 Havevej, DK-2970 Hørsholm (DK).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC,  
VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

(88) Date of publication of the international search report:  
25 March 2004

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

WO 2003/037361 A3

(54) Title: USE OF TISSUE FACTOR AGONIST OR TISSUE FACTOR ANTAGONIST FOR TREATMENT OF CONDITIONS  
RELATED TO APOPTOSIS

(57) Abstract: The present invention relates to use of FVII and/or FVIIa and/or another TF agonist and/or FVIIa and/or another TF  
antagonist in therapeutic treatment of pathological conditions increased or decreased cell apoptosis is required.

# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/DK 02/00727

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K38/48 A61K38/36

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, MEDLINE, WPI Data, CHEM ABS Data, BIOSIS, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GREENO E W ET AL: "Apoptosis is associated with increased cell surface tissue factor procoagulant activity." LABORATORY INVESTIGATION, vol. 75, no. 2, August 1996 (1996-08), pages 281-289, XP002902825 ISSN: 0023-6837 page 286, right-hand column	1.
A	---	2-19
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

17 June 2003

Date of mailing of the international search report

- 7. 07. 2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

YVONNE SIÖSTEEN /EÖ



## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/DK 02/00727

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>TAKEYA H ET AL: "Thrombosis and apoptosis"            DATABASE PUB MED / NCBI,            page 1 XP002902826            PMID 9256006            &amp; RINSHO BYORI, [Online]            vol. 45, no. 7, July 1997 (1997-07), pages            614-620,            Retrieved from the Internet:            &lt;URL:http://www.ncbi.nlm.nih.gov/entrez/quer            y.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uid..            .&gt; [retrieved on 2003-02-11]</p>	1
A	---	2,5,7,9, 12,13, 17,18
X	<p>WO 99 03498 A (NOVONORDISK AS)            28 January 1999 (1999-01-28)            page 2, line 29; example 3            page 5, line 1 - line 3; examples 5,6            page 13, line 15 - line 22</p>	3-6, 8-17,19
X	<p>WO 94 27631 A (PETERSEN LARS CHRISTIAN            ;NOVONORDISK AS (DK); HART CHARLES E            (US);) 8 December 1994 (1994-12-08)            page 5, line 27</p>	9,12,13
X	<p>YASUSADA KAWADA ET AL: "Successful            treatment of an infant with fulminant            hepatitis by factor VII concentrate."            JAPANESE JOURNAL OF CLINICAL HEMATOLOGY,            vol. 30, no. 11, 1989, pages 1982-1986,            XP002902827            the whole document</p>	9,12,13
X	<p>WO 01 05353 A (PETERSEN LARS CHRISTIAN            ;EZBAN MIRELLA (DK); NOVO NORDISK AS            (DK);) 25 January 2001 (2001-01-25)            page 3, line 26 - line 30</p>	3-6,8, 10,11, 14-17,19
A	<p>page 10, line 7 - line 20            page 8, line 13 - line 19; claims 14-16            page 4, line 6 - line 7</p>	1,2,7,9, 12,13,18
A	<p>CH. WALTHER ET AL: "Ein neuer Fall von            Hypoproconvertinämie (Faktor VII-Mangel),            zugleich Bericht einer            Substitutionsbehandlung während eines            stereotaktischen Eingriffes beim            Parkinsonsyndrom."            ARCHIV FÜR KLINISCHE MEDIZIN,            vol. 215, 1968, pages 161-173, XP002902828            the whole document</p>	9,12,13
	---	
	-/--	

## INTERNATIONAL SEARCH REPORT

International A on No  
PCT/DK 02/00727

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 16789 A (BEKI AB) 8 April 1999 (1999-04-08)  page 6, line 20 - line 22 ---	1,2,5,7, 9,12,13, 17,18
A	MARK M. KOCKX ET AL: "Decreased apoptosis and tissue factor expression after lipid lowering." CIRCULATION, vol. 102, no. 13, 2000, page e99 XP002902829 the whole document ---	1,2,5,7, 9,12,13, 17,18
A	DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; October 1996 (1996-10) LIBBY P ET AL: "Macrophages and atherosclerotic plaque stability." Database accession no. NLM8937525 XP002902830 abstract & CURRENT OPINION IN LIPIDOLOGY. UNITED STATES OCT 1996, vol. 7, no. 5, October 1996 (1996-10), pages 330-335, ISSN: 0957-9672 ---	1,2,5,7, 9,12,13, 17,18
X	WO 94 05328 A (MUELLER BARBARA M ;SCRIPPS RESEARCH INST (US); RUF WOLFRAM (US); E) 17 March 1994 (1994-03-17) the whole document ---	3,5,8, 10,14,17
A	MICHAEL E. BROMBERG ET AL: "Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation" PROC. NATL. ACAD. SCI., vol. 92, August 1995 (1995-08), pages 8205-8209, XP002244648 the whole document ---	3-6,8, 10,11, 14-17,19
A	WO 01 30333 A (JIAO JIN AN ;TAYLOR DEAN P (US); WONG HING C (US); LEUPSCHEN LAWRE) 3 May 2001 (2001-05-03) page 23, line 15 ---	3-6,8, 10,11, 14-17,19
A	US 5 833 982 A (BREGENGAARD CLAUS ET AL) 10 November 1998 (1998-11-10)  the whole document -----	3-6,8, 10,11, 14-17,19

# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/UK 02/00727

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-11, 17-19  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: 1, 3-5, 7-12, 14-15, 17, 19  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 12-13, 1, 2, 5(partly, 7, 9, 17(partly),18

Use of a tissue factor agonist for the manufacture of a medicament for treatment of diseases associated with undesired apoptosis of a cell population according to claims 12-13 and claims 1, 2, 5 (partly), 7, 9, 17 (partly), 18.

2. Claims: 14-16, 3, 4, 5 (parly), 6, 8, 10, 11, 17 (partly),  
19

Use of a tissue factor antagonist for the manufacture of a medicament for treatment of diseases where induction of apoptosis of a cell population is desired according to claims 14-16 and claims 3, 4, 5 (partly), 6, 8, 10, 11, 17 (partly), 19.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.1

Claims Nos.: 1-11,17-19

Claims 1-11,17-19 relate to methods of treatment of the human or animal body by surgery or by therapy/diagnostic methods practised on the human or animal body/Rule 39.1.(vi). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

-----

## Continuation of Box I.2

Claims Nos.: 1,3-5, 7-12, 14-15,17,19

## Invention I:

Present claims 12, 1,5,7,9 and 17 relate to a method or use defined by reference to desirable characteristics or properties, namely "a tissue factor agonist". The claims cover all compounds defined by reference to a desirable pharmacological property having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds (Factor VII and Factor VIIa). The expression "disease or condition associated with undesired apoptosis of a cell population" in claim 12 is not well defined. It is not fully possible to determine the diseases for which protection might legitimately be sought. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the method or use by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the use of Factor VII and Factor VIIa for the manufacture of medicament for treatment of the diseases mentioned in claim 9.

## Invention II

Present claims 14, 15, 3,4,5 8, 10, 11 17and 19 relate to a method or use defined by reference to desirable characteristics or properties, namely "a tissue factor antagonist". The claims cover all compounds defined by reference to a desirable pharmacological property having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds (Factor



## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

VII modified with chloro methylketone). The expression "disease or condition associated with undesired apoptosis of a cell population" in claim 14 is not well defined. It is not fully possible to determine the diseases for which protection might legitimately be sought. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the use of Factor VII modified with chloro methylketone for the manufacture of medicament for treatment of the diseases mentioned in claim 10.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/DK 02/00727

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9903498	A	28-01-1999	AU 8101698 A WO 9903498 A1 EP 1005361 A1 JP 2001510168 T US 6268163 B1 US 2003040481 A1 US 6461610 B1	10-02-1999 28-01-1999 07-06-2000 31-07-2001 31-07-2001 27-02-2003 08-10-2002
WO 9427631	A	08-12-1994	AT 210458 T AU 703110 B2 AU 6956094 A CA 2162726 A1 DE 69429429 D1 DE 69429429 T2 DK 699075 T3 EP 0699075 A1 ES 2169074 T3 HU 73329 A2 JP 8510746 T PT 699075 T WO 9427631 A1 US 6168789 B1 US 5817788 A US 6183743 B1 US 6039944 A US 5788965 A US 5861374 A US 5833982 A	15-12-2001 18-03-1999 20-12-1994 08-12-1994 24-01-2002 16-05-2002 11-03-2002 06-03-1996 01-07-2002 29-07-1996 12-11-1996 31-05-2002 08-12-1994 02-01-2001 06-10-1998 06-02-2001 21-03-2000 04-08-1998 19-01-1999 10-11-1998
WO 0105353	A	25-01-2001	AU 5807500 A BR 0012408 A CA 2378249 A1 CZ 20020040 A3 WO 0105353 A2 EP 1200116 A2 NO 20020130 A US 2002193302 A1	05-02-2001 12-03-2002 25-01-2001 16-04-2003 25-01-2001 02-05-2002 13-03-2002 19-12-2002
WO 9916789	A	08-04-1999	AU 9291198 A CA 2305681 A1 EP 1019438 A1 JP 2001518287 T WO 9916789 A1 US 6296850 B1 US 2002081310 A1 US 2002197657 A1	23-04-1999 08-04-1999 19-07-2000 16-10-2001 08-04-1999 02-10-2001 27-06-2002 26-12-2002
WO 9405328	A	17-03-1994	AU 5093593 A WO 9405328 A1	29-03-1994 17-03-1994
WO 0130333	A	03-05-2001	AU 1240301 A CA 2387857 A1 CN 1390123 T EP 1223921 A2 JP 2003512423 T WO 0130333 A2	08-05-2001 03-05-2001 08-01-2003 24-07-2002 02-04-2003 03-05-2001
US 5833982	A	10-11-1998	US 5788965 A	04-08-1998

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/DK 02/00727

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5833982	A	US 5817788 A	06-10-1998
		AU 735012 B2	28-06-2001
		AU 3090697 A	07-01-1998
		BR 9709661 A	25-04-2000
		CN 1221427 A	30-06-1999
		CZ 9803946 A3	14-04-1999
		WO 9747651 A1	18-12-1997
		EP 0910580 A1	28-04-1999
		HU 0003077 A2	28-12-2000
		JP 2000513720 T	17-10-2000
		KR 2000016415 A	25-03-2000
		NO 985668 A	04-02-1999
		PL 330365 A1	10-05-1999
		US 6168789 B1	02-01-2001
		US 6183743 B1	06-02-2001
		US 5997864 A	07-12-1999
		ZA 9705013 A	08-12-1997
		AU 4014295 A	15-05-1996
		BR 9509135 A	03-11-1995
		CA 2203280 A1	02-05-1996
		CZ 9701228 A3	12-11-1997
		EP 0789759 A1	20-08-1997
		HU 78098 A2	28-10-1999
		JP 11500408 T	12-01-1999
		NO 971878 A	23-06-1997
		PL 319813 A1	01-09-1997
		WO 9612800 A1	02-05-1996
		US 6039944 A	21-03-2000
		AT 210458 T	15-12-2001
		AU 703110 B2	18-03-1999
		AU 6956094 A	20-12-1994
		CA 2162726 A1	08-12-1994
		DE 69429429 D1	24-01-2002
		DE 69429429 T2	16-05-2002
		DK 699075 T3	11-03-2002
		EP 0699075 A1	06-03-1996
		ES 2169074 T3	01-07-2002
		HU 73329 A2	29-07-1996
		JP 8510746 T	12-11-1996
		PT 699075 T	31-05-2002
		WO 9427631 A1	08-12-1994
		US 5861374 A	19-01-1999
		AU 672357 B2	03-10-1996
		AU 1449892 A	06-10-1992
		AU 703760 B2	01-04-1999
		AU 7192096 A	06-02-1997
		CA 2103546 A1	29-08-1992